Art

J-GLOBAL ID：202102270483766838   Reference number：21A0019203

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

体細胞対生殖系列BRCA変異を有する固形腫瘍患者に対するPARP阻害剤による類似反応率および生存:Meta解析および系統的レビュー【JST・京大機械翻訳】

Author (9)： Mohyuddin Ghulam Rehman (University of Kansas, Kansas City, USA) ,  Aziz Muhammad (Department of Internal Medicine, University of Toledo, Toledo, USA) ,  Britt Alec (Department of Internal Medicine, University of Kansas, Kansas City, USA) ,  Wade Lee (University of Toledo Libraries, Toledo, USA) ,  Sun Weijing (Division of Medical Oncology, University of Kansas Cancer Center, Kansas City, USA) ,  Baranda Joaquina (Division of Medical Oncology, University of Kansas Cancer Center, Kansas City, USA) ,  Al-Rajabi Raed (Division of Medical Oncology, University of Kansas Cancer Center, Kansas City, USA) ,  Saeed Anwaar (Division of Medical Oncology, University of Kansas Cancer Center, Kansas City, USA) ,  Kasi Anup (Division of Medical Oncology, University of Kansas Cancer Center, Kansas City, USA)
Material： BMC Cancer (Web)
Volume： 20  Issue： 1  Page： 1-9  Publication year： 2020 
JST Material Number： U7305A  ISSN： 1471-2407  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： PARP inhibitors (PARPi) have r...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0019203&from=J-GLOBAL&jstjournalNo=U7305A") }}

Thesaurus term： *somatic cell ,  clinical trial ,  percent conversion ,  effectiveness ,  screening(inspection) ,  meta-analysis ,  *solid tumor ,  systematic review
Semi thesaurus term： 悪性腫瘍 ,  無増悪生存期間 ,  *生殖系列 ,  *PARP阻害剤 , 【Automatic Indexing@JST】

Author keywords (5)： PARP inhibitors ,  BRCA ,  Somatic ,  Germline ,  Meta-analysis

JST classification (4)： Molecular genetics in general  (EC02010J) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Genetic variation  (EC01030Y) ,  Tumors(=neoplasms)of female genitalia and fetus  (GS04000K)

Reference (43)：

• Cancer; BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nature reviews; R Roy, J Chun, SN Powell; 12; 2011; 68-78; citation_id=CR1
• Gynecologic Oncol; Two decades beyond BRCA1/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy; CS Walsh; 137; 2015; 343-350; 10.1016/j.ygyno.2015.02.017; citation_id=CR2
• JAMA.; Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers; KB Kuchenbaecker, JL Hopper, DR Barnes; 317; 2017; 2402-2416; 10.1001/jama.2017.7112; citation_id=CR3
• Cancer.; Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian; J Mersch, MA Jackson, M Park; 121; 2015; 269-275; 10.1002/cncr.29041; citation_id=CR4
• JNCI; Cancer risks in BRCA2 mutation carriers; TBCL Consortium; 91; 1999; 1310-1316; 10.1093/jnci/91.15.1310; citation_id=CR5

Terms in the title (11)： 体細胞 ,  生殖系列 ,  変異 ,  固形腫瘍 ,  患者 ,  PARP阻害剤 ,  類似 ,  反応率 ,  生存 ,  解析 ,  系統的レビュー